InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Silexion Therapeutics Corp

SLXN Clue Score15
Israel Fiscal year ends December CIK 0002022416
$0.21 -8.64% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.21 −94.64% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 16 Aug 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−4.7Net income−5.1EPS, diluted44.23Fiscal year 2024Operating income−12.6Net income−16.5EPS, diluted394.94Fiscal year 2025Operating income−11.6Net income−11.9EPS, diluted8.96
FY2023FY2024FY2025
Operating income −4.7 −12.6 −11.6
Net income −5.1 −16.5 −11.9
Growth
EPS, diluted 44.23 394.94 8.96

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−4.5Capital expenditure−0.0Free cash flow−4.5Fiscal year 2024Operating cash flow−8.4Capital expenditure−0.0Free cash flow−8.4Fiscal year 2025Operating cash flow−10.8Capital expenditure−0.0Free cash flow−10.8
FY2023FY2024FY2025
Operating cash flow −4.5 −8.4 −10.8
Capital expenditure −0.0 −0.0 −0.0
Free cash flow −4.5 −8.4 −10.8
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash4.6Shareholders’ equity−15.5Fiscal year 2024Cash1.2Shareholders’ equity−4.0Fiscal year 2025Cash6.0Shareholders’ equity2.6
FY2023FY2024FY2025
Cash 4.6 1.2 6.0
Shareholders’ equity −15.5 −4.0 2.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a n/a −457.6%
−97.2% −577.0% −165.1%
Balance and payout
42.9% 239.3% 63.9%